Chronic Disease
Programs for chronic condition management and prevention.
Promoting Integration of Primary and Behavioral Health Care: States
The purpose of this program is to: promote full integration and collaboration in clinical practices between physical and behavioral health care; support the improvement of integrated care models for physical and behavioral health care to improve overall wellness and physical health status; and promote the implementation and improvement of bidirectional integrated care services, including evidence-based or evidence-informed screening, assessment, diagnosis, prevention, treatment, and recovery services for mental and substance use disorders, and co-occurring physical health conditions and chronic diseases.
Promoting Cancer Surveillance Workforce, Education, and Data Use
This NOFO will implement educational activities to support the registry workforce, establish and maintain collaborations with cancer partners, and develop tools to support and enhance data quality and completeness. These efforts will expand registrars’ capacity, enhance recruitment and retention, and promote cancer surveillance data. The bolstering of the cancer registrar workforce will strengthen NPCR registries’ capacity to comply with Public Law 102-515, the Cancer Registries Amendment Act, and submit timely, accurate, and complete cancer data.
Transforming Pediatrics for Early Childhood (TPEC) Program
The Transforming Pediatrics for Early Childhood Program (TPEC) will advance the U.S. Department of Health and Human Services’ Make America Healthy Again (MAHA) priorities by preventing chronic disease early in life and promoting healthy development in early childhood. TPEC recipients - organizations with statewide or tribal reach - will place early childhood development (ECD) experts in local pediatric practices to deliver team-based care to young children and their families. Recipients will improve the quality and cost effectiveness of pediatric primary care by delivering a comprehensive team-based approach that focuses on factors critical to child development. Through this approach, pediatric primary care staff will: Screen families for their needs related to mental health, housing, nutrition, and child development; Build safe, stable, and nurturing relationships between caregivers and their children; Educate caregivers on developmental milestones and how to watch for them; and Make sure that families get referrals and access to additional or specialized support. TPEC recipients will: Place early childhood development (ECD) experts in pediatric practices that primarily serve families covered by Medicaid/Children’s Health Insurance Program (CHIP) and deliver high-quality ECD services using a team-based approach.Build the skills of pediatric primary care staff statewide to deliver high-quality ECD services using a team-based approach. Improve statewide administrative policies and financing strategies to expand and sustain team-based pediatric primary care, improving the standard of care for all young children. TPEC will result in measurable improvements in service delivery rates and early childhood development outcomes.
Agriculture and Food Research Initiative Strengthening Agricultural Systems
The long-term goal of the Agriculture and Food Research Initiative - Strengthening Agricultural Systems (SAS) Notice of Funding Opportunity (NOFO) is to help transform the U.S. food and agricultural system to increase agricultural production while enhancing farmer prosperity. Achieving this goal will require transdisciplinary approaches to address current and future food and agricultural challenges within the context of the economic viability of farm operations, quality of life for farmers and society as a whole, and the most efficient use of resources. NIFA is soliciting applications to support: 1. At least one of the following Strengthening Agricultural Systems sub-priorities: a. New Uses and Expanding Markets for Agriculture and Forestry Products b. Solutions to Pests and Diseases of Plants or Animals c. Combating Food and Diet-Related Chronic Diseases 2. Artificial Intelligence for K-12 Food and Agricultural Sciences *See AFRI SAS NOFO for each program area specific application due date.
Fiscal Year (FY) 2026 National Technical Assistance Programs (NTAP) Cooperative Agreements
The FY 2026 National Technical Assistance Programs (NTAP) cooperative agreement supports three national organizations to develop and deliver technical assistance (TA) to existing and potential health centers with a focus on: Supporting the delivery of comprehensive, high-quality primary health care; improving chronic disease management, nutrition, and preventive services; improving operational effectiveness, efficiency, and quality; addressing emergent public health needs and priorities; complying with and exceeding Health Center Program and supplemental funding requirements.
Telehealth Nutrition Services Network Grant Program
The Telehealth Nutrition Services Network Grant Program will support telehealth networks that improve access to quality health care services through telehealth technology. This program will focus on chronic disease prevention and chronic disease management through comprehensive telehealth nutrition services.
Early Childhood Comprehensive Systems SEED Project: Scaling Effective Early Childhood Systems Development (ECCS SEED)
The purpose of the Early Childhood Comprehensive Systems SEED Project: Scaling Effective Early Childhood Systems Development (ECCS SEED) is to address the root causes of chronic disease in early childhood by improving families’ access to health care, screening kids early for physical and mental health needs, and connecting parents to services that enable them to provide for their children. The ECCS SEED Project will partner with states and communities to support evidence-based strategies that improve access to quality care for prenatal-to-age-5 (P-5) families and promote healthy child development and family well-being.
Providers Clinical Support System - Universities
The purpose of this program is to fully prepare graduate-level health professional students to understand, identify, intervene, and treat patients with a substance use, misuse and substance use disorder (SUD), upon becoming licensed practitioners. Students will gain the knowledge of the medical consequences of SUD as a chronic illness, evidence-based treatment options, and the impact of recovery supports. Students will gain practical experience working with practitioners treating SUD as well as from individuals living in long-term recovery.
Centers for AIDS Research (CFAR)
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by continuing support for the Centers for AIDS Research (CFAR). The national network of CFARs cooperates with other HHS-funded HIV/AIDS programs to establish and maintain the collaborations and infrastructure required to carry out innovative implementation science research for ending the HIV epidemic domestically. Addressing a complex chronic disease, HIV/AIDS research requires broad scientific expertise, access to unique biological samples, and cutting-edge research technologies that extend beyond the needs of individual research groups. The CFAR program strengthens HIV/AIDS research by providing infrastructure that fosters multidisciplinary collaborations, maximizes efficiencies by reducing duplication of efforts, and leverages economies of scale to facilitate the translation of basic research findings into new HIV treatment, prevention, and cure approaches. A core mission of the CFAR program is to support and mentor early-career investigators and investigators new to HIV/AIDS research by funding pilot studies, emerging research opportunities, and high-risk/high-impact collaborative studies. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
Engaging faith-based organizations to sustain lifesaving HIV and TB services in Ethiopia
The Award Ceiling for Year 1 is 0 (none). CDC anticipates an Approximate Total Fiscal Year Funding amount of $5,000,000 for Year 1, subject to the availability of funds. This NOFO will engage faith-based organizations (FBOs) to support and sustain lifesaving HIV, TB, and cervical cancer services in Ethiopia. HIV services will include: • HIV testing. • HIV prevention, including vertical transmission. • Adult and pediatric HIV care and treatment. Through this project, you will work with faith communities to provide and link people with lifesaving HIV services. You will serve: • People at high risk of acquiring HIV. • Undiagnosed people living with HIV • People living with HIV at risk of interrupting their treatment. • Pregnant and breastfeeding women. • People living with HIV who may face barriers to accessing conventional health facility services. You will be expected to implement cost-efficient models and integrate them with the routine health-care delivery system to reach undiagnosed people living with HIV, people living with HIV who have defaulted from care, and people at high risk of acquiring HIV, ensuring their access to critical, lifesaving HIV and TB services. This NOFO will support activities that promote country ownership and country-led plans that enable greater sustainability. Programs supporting other public health threats and emergencies in Ethiopia may also be included in this NOFO.
A Demonstration to Scale Innovative Person-Centered Approaches to Falls Prevention through Clinical-Community Partnerships
The purpose of this funding announcement is to demonstrate and evaluate the scalability of person-centered and evidence-based approaches to falls prevention that leverage clinical and community partnerships and related data and technology tools. ACL intends to award a single cooperative agreement to one grantee for a three-year project period with the expectation that the grantee will fund up to three demonstrations. This award will build on the ACL Innovation Lab to demonstrate the scaling of person-centered and evidence-based approaches to falls prevention and related chronic disease management programs through community care hubs and their respective clinical partners and community-based organizations in the aging services network. The successful applicant will be expected to collaborate with ACL in the design and implementation of these demonstrations in the scalability of falls prevention and related chronic disease management interventions through approximately three advanced community care hubs that support care transitions and screening for the risk of falls. They should also have the capacity to 1) do rapid cycle evaluation to iterate and improve the impact of the interventions as they are scaled and, 2) administer sub-awards to community care hubs that can implement and scale person-centered interventions enabled by artificial intelligence, data analytics, assistive technology, virtual delivery of interventions, tools to support consumer behaviors, and related data infrastructure.
Lifespan Respite Care Program: Grants to New States and States Re-Establishing Their Core Respite Infrastructures
ACL is seeking applications from eligible state agencies that will establish, or reestablish, state and local coordinated Lifespan Respite Care systems and deliver respite care and related services to family caregivers of children and adults across all age groups, disabilities, and chronic conditions as defined in the statute. Funds supplement, not replace existing funds. Eligible states applying must fall within one of the following two categories: 1) New States that have not previously received a grant under this program. 2) Returning States who have had at least one (1) Lifespan Respite Care Program grant, but whose programs have gone dormant or lapsed since federal funding ended, and desire to re-establish their core state respite infrastructures, rather than apply for a Program Enhancement grant. ACL will fund approximately four (4) cooperative agreements for the 3-year project period. All programs must, from the outset, address the respite needs of all populations regardless of age, disability, or chronic condition of the care recipient population. Funded applicants shall use grant funds to serve all age groups and disabilities, provide new and emergency care services, recruit and train workers and volunteers, help families access care services and other authorized services as outlined in the Act. It is ACL’s expectation that all grantees will, no later than the second and third years of the grant project period, provide respite services while continuing to build their statewide respite infrastructure. Awardees under this funding opportunity will work with ACL to implement the data collection and reporting requirements under Section 2904 of the Lifespan Respite Reauthorization Act of 2020.
Lifespan Respite Care Program: State Program Enhancement Grants
ACL is seeking applications from eligible state agencies that will advance the provision of respite services through their statewide Lifespan Respite Care system as outlined in the Act. Eligible states applying must use funds to enhance respite services through their existing Lifespan Respite Care system and have already received a program enhancement grant and looking to continue to scale and build collaborations and partnerships. Funds supplement, not replace existing funds. The goal of the program is to enhance state systems and capacities to deliver respite care and related services to family caregivers of children and adults across all age groups, disabilities, and chronic conditions. All programs must, from the outset, address the respite needs of all populations regardless of age, disability, or chronic condition of the care recipient population. Funded applicants will continue advancing goals that build collaborations and partnerships statewide, expand volunteer options, offer respite provider training, find and reduce service gaps through outreach and engagement, and further meaningful caregiver-focused strategies and authorized services as outlined in the Act. ACL will fund approximately ten (10) cooperative agreements over the course of the 3-year project period. Awardees under this funding opportunity will work with ACL to implement the data collection and reporting requirements under Section 2904 of the Lifespan Respite Reauthorization Act of 2020.
HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) - Building Engagement, Assistance, Capacity, Outreach, and Networks (BEACON) Center
40-75% percent of individuals with opioid use disorder (OUD) have co-occurring chronic pain (CP), which impacts their ability to fully engage in treatment. Effective management of both conditions is hindered by siloed medical disciplines and health systems. HEAL Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR) was funded in FY21 to test novel interventions for the management of co-occurring CP and OUD at the patient level. This initiative will test different implementation strategies and other approaches to address scalability and sustainability of evidence based practices for CP and OUD from a health system perspective. Studies will engage key decision leaders in health systems including but not limited to: peer specialists, clinicians, health system leaders, and payers. Studies will execute a single hybrid II/III implementation-effectiveness trial to focus on collaborative care models and implementation strategies to meaningfully integrate CP and OUD service provision in diverse health settings. These studies will address complex factors that influence the ability to scale and sustain effective and integrated care for CP and OUD. The BEACON Center will provide: (1) network coordination support, (2) capacity building at the intersection of CP, OUD, and implementation science, (3) annual surveys/qualitative activities to understand different barriers and attitudes impacting access and sustained use to integrated CP and OUD service delivery, (4) develop important resources for key stakeholder audiences that can inform/improve sustainability and scalability of evidence-based practices. The National Institute on Drug Abuse (NIDA) in partnership with National Institute on Alcohol and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Mental Health (NIMH), and National Center for Complementary and Integrative Health (NCCIH), and National Institute of Neurological Disorders and Stroke (NINDS) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for research on the effective management of OUD and CP. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the U2C activity code. Investigators with expertise and insights into this area of CP management and OUD/opioid misuse are encouraged to begin to consider applying for this new NOFO. In addition, collaborative investigations combining expertise in community-based participatory research approaches, implementation science, and other strategies to amplify scalability and sustainability will be encouraged and, these investigators should also begin considering applying for this NOFO. Grant authorities that allow NIDA to forecast this opportunity are as follows: 42 U.S.C. § 241 and § 284.
Novel approaches to support therapeutic development in ultra-rare cancers
The purpose of this program is to support new approaches that can be applied to facilitate therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers. Specific areas of interest include, but are not limited to, the following examples: • Development of infrastructure for a coordination network and data repository for patient-level data across institutions and internationally to support drug development and regulatory decision-making for one or more ultra-rare cancers. • Investigations to explore opportunities to develop and validate early clinical endpoints and other novel efficacy endpoints for evaluation of treatments for ultra-rare cancers. • Development and implementation of a collaborative multi-stakeholder effort to support generation and use of real-world data leveraging a registry framework for use in development of new therapies for pediatric patients with diffuse midline glioma (DMG) (including diffuse intrinsic pontine glioma, DIPG). • Innovative approaches to identify new biologically-driven opportunities for clinical development of previously approved drugs or biologics (hereafter referred to as drugs), including drugs for which development has been discontinued, in ultra-rare cancers. • Research to develop novel approaches to preserve the availability of drugs for which commercial developers have discontinued adult development that have strong potential in ultra-rare cancers but lack financial incentives for commercial development • Development of methods to incorporate use of telemedicine and/or pragmatic trial design elements (e.g., collecting laboratory and/or imaging data from local facilities) for patient assessments to facilitate enrollment of patients with ultra-rare cancers • Development of nanoparticle-based delivery approaches for therapeutic nucleic acids targeting onco-fusion transcription factors in metastatic tumor animal models using targeted bioPROTAC degradation or genomic editing strategies. Successful efforts should demonstrate effective delivery and expression in-vivo to tumor cells, and downregulation of the target transcription factor protein while minimizing off-target effects and limiting sequestration of the nanoparticle by the liver, spleen, and lungs. • Research to exhaustively characterize the plasma-membrane protein expression (surfaceome) of an ultra-rare cancer and the presumed healthy tissue of origin, as well as the resident-tissue stem cells, by single-cell transcriptomics and proteomics. These studies, and available correlative database analyses, should be designed to identify possible combinatorial signatures of plasma membrane proteins unique to the ultra-rare tumor. Tumors of interest include Sclerosing epithelioid fibrosarcoma and atypical teratoid rhabdoid tumors (ATRT).
Collaborative Surveys to Provide Inputs into Vaccine-Related Economic Evaluations
The purpose of this notice of funding opportunity (NOFO) is to support research to obtain timely input from nationally representative samples of the public, including but not limited to patients and caregivers, on critical economic immunization issues of importance to public health. For example, productivity losses of child caregivers can be used as an input for a cost-effectiveness analysis of a pediatric vaccine in development. The objectives of this NOFO are: 1) to conduct multiple surveys of the public over the project period to collect immunization-related economic data, using scientifically sound methods with adequate response rates that produce generalizable results; and 2) to disseminate the results broadly to assist in economic evaluations for new vaccines and developing strategies to improve immunization coverage. Surveyed members of the public should be at least18 years old or older, and should include subpopulations such as pregnant women, parents of children aged 0–17 years, and persons with chronic medical conditions.
Causal Hypotheses on the Oral-Systemic Health Impacts of Human Behaviors among People with Chronic Conditions
The National Institute of Dental and Craniofacial Research (NIDCR) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for innovative research on the factors that cause human behaviors and the oral-systemic health impacts of those behaviors to enhance health, lengthen life, and reduce illness and disability among people with chronic conditions. Causal hypotheses may include biological, biopsychosocial, congenital, environmental, interpersonal, neurological, psychological, and comorbidity factors that—individually, sequentially, or in combination—contribute to human behaviors and oral-systemic health outcomes, with impacts that may be direct or traceably distal. Applications that propose projects to develop or refine causal hypotheses, e.g., causal explanation and causal inference—rather than statistical association, also are encouraged. Project results should be poised for clinical trials translation to prevent, treat, and manage dental, oral, and craniofacial (DOC) and related conditions. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Investigators with expertise and insights into this area of behavioral, biological, biopsychosocial, public, and social sciences are encouraged to consider applying for this new NOFO. In addition, collaborative investigations combining expertise in dental, oral, craniofacial, and systemic health over the life course, including care and services, will be encouraged, and these investigators also should begin to consider applying. NIDCR is authorized to forecast this opportunity under the Public Health Service Act (42 U.S.C §§ 241 and 284) and federal regulations (42 CFR Part 52 and 2 CFR Part 200).
HEAL Initiative: Integrative Management of Chronic Pain and Opioid Use Disorder (OUD) for Whole Recovery: Health Systems
Forty to sixty percent of individuals with opioid use disorder (OUD) have co-occurring chronic pain (CP), which impacts their ability to fully engage in treatment. Effective management of both conditions is hindered by siloed medical disciplines and health systems. HEAL Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR) was funded in FY21 to support 11 unique clinical trials to test novel interventions for the management of co-occurring chronic pain and OUD at the patient-level. The current NOFO will develop strategies to address barriers to the sustainable and effective delivery of integrated OUD/pain care at the health systems level. IMPOWR identified patient interventions that were effective and ready to implement. The current NOFO will address how health systems could be improved to facilitate the use of effective integrative interventions, including the involvement and roles of peer specialists, clinicians, health system leaders and other key decision makers. Also, this NOFO will characterize where such care can be optimally and efficiently delivered. Studies will identify collaborative care models, implementation strategies, and other innovative health system approaches to meaningfully integrate CP and OUD service provision in health settings. These studies will address complex factors that influence the ability to scale and sustain effective collaborative and integrated care for pain and OUD. The National Institute on Drug Abuse (NIDA) in partnership with National Institute on Alcohol and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Mental Health (NIMH), and National Center for Complementary and Integrative Health (NCCIH), and National Institute of Neurological Disorders and Stroke (NINDS) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for research on the effective management of OUD and CP. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the RM1 activity code. Investigators with expertise and insights into this area of chronic pain management and OUD/opioid misuse are encouraged to begin to consider applying for this new NOFO. In addition, collaborative investigations combining expertise in community-based participatory research approaches, implementation science, and other strategies to amplify scalability and sustainability will be encouraged and, these investigators should also begin considering applying for this NOFO.
Notice of Intent to Publish a Funding Opportunity Announcement for ClinGen Genomic Curation Expert Panels
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), with other NIH Institutes and Centers (ICs) - National Eye Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute on Deafness and Other Communication Disorders, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Center for Advancing Translational Sciences, and National Cancer Institute - intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for the establishment and continuation of Genomic Curation Expert Panels that manually curate, review and define the clinical relevance of genes and variants as part of the NIH established and funded Clinical Genome Resource (ClinGen). Despite advances in genomic sequencing technology and increasing adoption in clinical practice, there are many genomic variants with unknown significance (VUS), and there is limited understanding of their function. This presents barriers to genomic and precision medicine. To address this need for better knowledge about the links between genes, variants, and disease, this NOFO will facilitate the development of Expert Panels to select genes and variants associated with diseases or conditions of high priority for participating NIH Institutes and Centers (ICs) and to systematically determine their clinical significance for diagnosis and treatment of these diseases or conditions. The Expert Panels funded through this NOFO are required to utilize the NHGRI ClinGen and the NCBI ClinVar procedures, interfaces, tools, and informatics infrastructure. Ultimately, these expert panels contribute to an authoritative, centralized, and public resource, through aggregation, evaluation, and sharing of expert-curated data about genetic conditions, and the variants that cause them.
Notice of Intent to Publish a Funding Opportunity Announcement for HIV Pediatric, Adolescent and Maternal Clinical Trials
The Eunice Kennedy Shriver National Institute of Child Health and Human Development intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for research focused on high-priority HIV studies for infants, children, youth and young adults (AYA), and maternal populations. An HIV clinical trials network focused exclusively on pediatric and maternal populations will innovate and conduct rigorously designed, collaborative clinical trials in partnership with site consortia to address high-priority research areas in HIV and related comorbidities and coinfections. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the UM2 activity code. Investigators with expertise and insights into this area of HIV are encouraged to begin to consider applying for this new NOFO. In addition, collaborative investigations combining expertise in chronic and infectious diseases, pediatrics, adolescent medicine, laboratory innovation, and cost-effectiveness will be encouraged and these investigators should also begin considering applying for this application.
Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Data Analysis Resource (U24 Clinical Trials Optional)
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) launched the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) in 2012 to determine how adolescent alcohol-related disruption of normal brain growth patterns of structure, related brain function, and psychiatric health affects brain functioning in emerging adulthood. The consortium uses an accelerated longitudinal design and has acquired data on over 800 individuals between the ages of 12 to 32 years. This wide age range covers the period before onset of drinking, the transition from adolescence to young adulthood, the critical period for binge drinking, and the time of maturing out. This unique dataset provides novel information on the enduring and transient consequences of adolescent drinking on adult brain function and behavior. Current studies on adults drinking do not have this type of data. Renewal of this limited competition NOFO will enable NCANDA to continue to follow these participants up to 37 years of age and acquire data critical to understanding how early versus late onset drinking during adolescence differentially impacts drinking behavior in adulthood. This limited competition renewal will provide valuable information for developing evidence-based alcohol prevention strategies and early intervention approaches to prevent the progression to more severe drinking and AUD thereby preventing the development of chronic disease, improving health outcomes, and increasing quality of life and longevity. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the U24 activity code. Investigators with expertise and insights into this area of integrative neuroscience are encouraged to begin to consider applying for this new NOFO.
Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Administrative Resource (U24 Clinical Trials Optional)
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) launched the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) in 2012 to determine how adolescent alcohol-related disruption of normal brain growth patterns of structure, related brain function, and psychiatric health affects brain functioning in emerging adulthood. The consortium uses an accelerated longitudinal design and has acquired data on over 800 individuals between the ages of 12 to 32 years. This wide age range covers the period before onset of drinking, the transition from adolescence to young adulthood, the critical period for binge drinking, and the time of maturing out. This unique dataset provides novel information on the enduring and transient consequences of adolescent drinking on adult brain function and behavior. Current studies on adults drinking do not have this type of data. Renewal of this limited competition NOFO will enable NCANDA to continue to follow these participants up to 37 years of age and acquire data critical to understanding how early versus late onset drinking during adolescence differentially impacts drinking behavior in adulthood. This limited competition renewal will provide valuable information for developing evidence-based alcohol prevention strategies and early intervention approaches to prevent the progression to more severe drinking and AUD thereby preventing the development of chronic disease, improving health outcomes, and increasing quality of life and longevity. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the U24 activity code. Investigators with expertise and insights into this area of developmental neuroscience are encouraged to begin to consider applying for this new NOFO.
Forecast to Publish a Funding Opportunity Announcement for Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Research Project Sites (U01 Clinical Trials Optional)
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) launched the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) in 2012 to determine how adolescent alcohol-related disruption of normal brain growth patterns of structure, related brain function, and psychiatric health affects brain functioning in emerging adulthood. The consortium uses an accelerated longitudinal design and has acquired data on over 800 individuals between the ages of 12 to 32 years. This wide age range covers the period before onset of drinking, the transition from adolescence to young adulthood, the critical period for binge drinking, and the time of maturing out. This unique dataset provides novel information on the enduring and transient consequences of adolescent drinking on adult brain function and behavior. Current studies on adults drinking do not have this type of data. Renewal of this limited competition NOFO will enable NCANDA to continue to follow these participants up to 37 years of age and acquire data critical to understanding how early versus late onset drinking during adolescence differentially impacts drinking behavior in adulthood. This limited competition renewal will provide valuable information for developing evidence-based alcohol prevention strategies and early intervention approaches to prevent the progression to more severe drinking and AUD thereby preventing the development of chronic disease, improving health outcomes, and increasing quality of life and longevity. Applications are not being solicited at this time. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the U01 activity code. Investigators with expertise and insights into this area of developmental neuroscience are encouraged to begin to consider applying for this new NOFO.
GPD Grant Forecast
THIS IS NOT A NOTICE OF FUNDING. THIS IS A GENERAL FORECAST ONLY. Grant and Per Diem (GPD) Program Introduction The GPD Program is VA’s largest transitional housing program for Veterans experiencing homelessness and is permanently authorized under Public Law 109-461. Since 1994, the GPD Program has awarded grants to community-based organizations to provide transitional housing with wraparound supportive services to assist vulnerable Veterans move into permanent housing. The grants are designed to meet Veterans at various stages as they move to stable housing. Community-based organizations receiving GPD grants offer focused transitional housing services through a variety of housing models targeted to different populations and needs of Veterans. The GPD program plays a vital role in the continuum of homeless services by providing supportive services to those Veterans who would otherwise be among the unsheltered homeless population. The result of GPD programs is that Veterans achieve residential stability, increase their skill levels and/or income, and obtain greater self-determination. Types of GPD Grants Transitional housing grants: Per Diem Only (PDO) grants provide funding in the form of per diem payments to reimburse grantees for the cost of care provided to Veterans in transitional supportive housing. Special Need grants target housing and services to specific populations of Veterans (e.g., women, Veterans with chronic mental illness, frail elderly Veterans, Veterans caring for minor dependents, terminally ill Veterans). Transition-In-Place (TIP) grants offer Veteran residents housing in which supportive services transition out of the residence over time, rather than the resident. Upon completion of the TIP services, the resident retains the unit as their permanent housing with no requirement to move. Other types of grants: Case Management grants support Veterans who were previously experiencing homelessness or who are at risk for homelessness so that they may obtain or retain permanent housing. Capital grants support the costs of acquiring, renovating, or constructing facilities and are only offered intermittently to improve existing facilities or to develop new transitional housing depending on VA's priorities and funding availability. Lists of current grantees are available on the GPD website. How to Apply for GPD Funding Not all grant types are available annually. When available, notices of funding can be found at the following locations: www.grants.gov and https://www.va.gov/homeless/gpd.asp. Application instructions are provided in each notice of funding. Each notice of funding will clarify specific eligibility criteria, application requirements, funding limitations, and other requirements. Applications are submitted through an online portal that is only available when there is an open notice of funding. Potential applicants who wish to see what was required for previous applications may review past notices of funding, available on the GPD provider website and www.grants.gov. Past notices of funding are not a guarantee of future requirements. Tentative Estimated GPD Award Schedule Specific dates are not able to be forecast. The follow tentative approximations are provided for general planning purposes. FY 2026 Case Management – GPD tentatively expects to offer a notice of funding around FY 2025 for case management awards starting approximately in FY 2026. FY 2027 PDO – GPD tentatively expects to offer a notice of funding around FY 2026 for PDO awards starting approximately in FY 2027. TIP – GPD tentatively expects to offer a notice of funding around FY 2026 for TIP awards starting approximately in FY 2027. FY 2028 GPD tentatively does not expect to offer a notice of funding for this timeframe. GPD may update this forecast closer to the time. THIS IS NOT A NOTICE OF FUNDING. THIS IS A GENERAL FORECAST ONLY.
Cooperative Agreement to Support Activities Related to Analgesics, Anesthetics, and Addiction (U01) Clinical Trials Allowed
To develop, disseminate, implement, and evaluate research needed in Anesthesia, Addiction Medicine and Pain Medicine in various fields of research. Specifically, research is needed in the following fields: function as a clinical trial endpoint and measurement of function in patients with chronic pain, outcome measures for clinical trials in stimulant use disorders, assessment of opioid clinical trials with active control in addition to placebo, neurodevelopmental outcome assessment of vulnerable pediatric patients exposed to anesthesia and opioid, and a living systematic review of pre-clinical studies of anesthetic neurotoxicity. Multiple awards may be considered. Applicants must propose a comprehensive evidence-based plan that advances appropriate prescribing of drug products intended for analgesia, anesthesia, and substance use disorders.
NHLBI Program Project Applications (P01 Clinical Trials Optional)
The National Heart, Lung, and Blood Institute (NHLBI) Program Project Grant (P01) supports research related to fundamental processes and diseases of the heart, blood and lymphatic vessels, lungs, and blood, including transfusion medicine, blood resources, and sleep disorders other programs including implementation science, health disparities, and translation research that address the mission of the Institute. This FOA requires a minimum of three interrelated research projects that investigate a complex biomedical theme or research question. The projects may be supported by core units, if justified, to facilitate economy of effort, space, and equipment. The NHLBI provides support for Program Project Grants (PPGs) in the belief that collaborative research efforts can accelerate the acquisition of knowledge more effectively than a simple aggregate of research projects that have no interaction or thematic integration. NHLBI is particularly interested in encouraging new scientific directions in PPGs. Use of the P01 activity code is viewed as an opportunity to attract scientists who have not traditionally been supported by the NHLBI. Further, the PPG environment presents an opportunity for emerging scientific leaders to gain insight into how to lead a successful scientific Program, and applicants will have the opportunity to include a project led by an Early Stage Investigator (ESI). All projects in the Program must be interrelated and have objectives that address a central theme within the scientific mandate of the NHLBI.